3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Breast Neoplasms
17
Brain Neoplasms
5
Neoplasm Metastasis
4
Neoplasms
3
Meningeal Neoplasms
3
Triple Negative Breast Neoplasms
2
Rectal Neoplasms
2
Colorectal Neoplasms
2
Colonic Neoplasms
2
Pathologic Complete Response
1
Multiple Myeloma
1
Metastatic Breast Cancer With a Isolated Brain Progression
1
Meningeal Carcinomatosis
1
Lymphoma, Non-Hodgkin
1
Lung Neoplasms
1
Hemangiosarcoma
1
HER2-positive Breast Cancer
1
Central Nervous System Diseases
1
Carcinoma, Non-Small-Cell Lung
1
Anatomic Stage II Breast Cancer AJCC v8
1
Anatomic Stage IA Breast Cancer AJCC v8
1
Adenocarcinoma
1
Interventions
Pemetrexed
18
Bevacizumab
9
Spinal Puncture
7
Radiotherapy
7
Specimen Handling
5
Methotrexate
5
Magnetic Resonance Spectroscopy
5
osimertinib
4
aflutinib
4
Trastuzumab
3
Topotecan
3
Temozolomide
3
Dexamethasone
3
trastuzumab deruxtecan
2
pembrolizumab
2
merphos
2
lorlatinib
2
Vitamin B 12
2
Rituximab
2
Radiotherapy, Intensity-Modulated
2
Folic Acid
2
Drug Therapy
2
Cytarabine
2
Cyclophosphamide
2
tucatinib
1
toripalimab
1
sintilimab
1
sacituzumab govitecan
1
pertuzumab
1
peginterferon alfa-2b
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Meningeal Carcinomatosis
×
tucatinib
×
Clear all
NCT05800275
2025-11-18
ETIC-LM
UNICANCER
Phase 2
Recruiting
30 enrolled